PET scans, image reconstruction, and ROI analysis of each PET scan were performed using an Inveon microPET/microCT rodent model scanner (Siemens Medical Solutions USA, Inc.) as described previously (20 (link)). Each tumor-bearing mouse was intravenously injected with 5–10 MBq of 64Cu-NOTA-rh-HGF and 5- to 10-min static PET scans were performed at various time points post-injection (p.i.). The tracer uptake was calculated as percentage injected dose per gram of tissue (%ID/g) (mean ± SD; ≥3 mice per group).
Denature studies were carried out to evaluate c-Met specificity of 64Cu-NOTA-rh-HGF in vivo, where a group of 3 mice were each injected with 5–10 MBq of sonicated-denatured tracer, 64Cu-NOTA-dnrh-HGF. Biodistribution studies were performed after the last PET scans at 24 h p.i. to validate the PET data. The tumors, liver and muscle were also frozen and cryosectioned for histologic analysis. Quantitative data were expressed as mean ± SD. Means were compared using the Student t test. P values of less than 0.05 were considered statistically significant.
Denature studies were carried out to evaluate c-Met specificity of 64Cu-NOTA-rh-HGF in vivo, where a group of 3 mice were each injected with 5–10 MBq of sonicated-denatured tracer, 64Cu-NOTA-dnrh-HGF. Biodistribution studies were performed after the last PET scans at 24 h p.i. to validate the PET data. The tumors, liver and muscle were also frozen and cryosectioned for histologic analysis. Quantitative data were expressed as mean ± SD. Means were compared using the Student t test. P values of less than 0.05 were considered statistically significant.
